IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin

• DOI: 10.1097/qad.0b013e3283471cae
• Publication Date: 2011-04-19T10:33:04Z
• Authors: Norma I Rallón; Vincent Soriano; Susanna Naggie; Clara Restrepo; David Goldstein; Eugenia Vispo; John McHutchison; José M Benito
• Keywords: Interleukin 28B; Pegylated interferon; Hepatitis C

A single nucleotide polymorphism (SNP) upstream of the IL28B gene (rs12979860) predicts sustained virological response (SVR) to peginterferon-ribavirin therapy in chronic hepatitis C patients. There is scarce information regarding influence this SNP on early viral kinetics during therapy, particularly patients coinfected with HIV, whom treatment lower than virus (HCV)-monoinfected patients.We selected 196 HIV/HCV-coinfected individuals who had completed a course and validated outcome for SVR. Association SNPs rapid, end-of-treatment responses [rapid (RVR), (EVR) end response, respectively] was assessed univariate multivariate analyses.Rate SVR study population 54%. Frequency CC genotype 44%. The distribution HCV genotypes as follows: HCV-1 57%, HCV-2 1%, HCV-3 30% HCV-4 12%. Compared CT/TT, associated significantly higher rates all on-treatment outcomes, after adjusting other predictors serum HCV-RNA, liver fibrosis staging. kept its predictive power did not achieve RVR or cEVR. association between outcomes significant only 1 4.IL28B strong predictor This effect mediated by an increase clearance first 12 weeks mainly seen infected 4.